Abstract
Background: Group A streptococcus (GAS) primarily colonizes the mucosal region of the upper respiratory tract, slowly leading to systemic infections. Thus, GAS-specific antibody responses are desirable at mucosal sites for early prevention against GAS colonization.
Methods: Herein, we developed a potent nanoliposomes-based delivery system for mucosally active lipid core peptide (LCP)-based vaccines. Results: Trimethyl chitosan (TMC)-coated liposomes that bore a B-cell epitope derived from GAS Mprotein, stimulated potent epitope-specific mucosal and systemic antibody titres after only one boost following intranasal immunization in Swiss outbred mice. The immune responses were durable even at day 139 post-primary immunization. Conclusion: The enhanced vaccine efficacy, lowered dose, and simple and cost-effective process of producing the coated nanoliposomes should be particularly useful in developing potent peptide-based vaccines to prevent infections at the mucosal sites.Keywords: Chitosan, group A streptococcus, lipopeptides, liposomes, nasal delivery, peptide vaccines.
Current Drug Delivery
Title:Highly Immunogenic Trimethyl Chitosan-based Delivery System for Intranasal Lipopeptide Vaccines against Group A Streptococcus
Volume: 14 Issue: 5
Author(s): Nirmal Marasini, Khairunnisa Abdul Ghaffar, Ashwini Kumar Giddam, Michael R. Batzloff, Michael F. Good, Mariusz Skwarczynski*Istvan Toth*
Affiliation:
- School of Chemistry and Molecular Biosciences, The University of Queensland, St Lucia, QLD 4072,Australia
- School of Chemistry and Molecular Biosciences, The University of Queensland, St Lucia, QLD 4072,Australia
Keywords: Chitosan, group A streptococcus, lipopeptides, liposomes, nasal delivery, peptide vaccines.
Abstract: Background: Group A streptococcus (GAS) primarily colonizes the mucosal region of the upper respiratory tract, slowly leading to systemic infections. Thus, GAS-specific antibody responses are desirable at mucosal sites for early prevention against GAS colonization.
Methods: Herein, we developed a potent nanoliposomes-based delivery system for mucosally active lipid core peptide (LCP)-based vaccines. Results: Trimethyl chitosan (TMC)-coated liposomes that bore a B-cell epitope derived from GAS Mprotein, stimulated potent epitope-specific mucosal and systemic antibody titres after only one boost following intranasal immunization in Swiss outbred mice. The immune responses were durable even at day 139 post-primary immunization. Conclusion: The enhanced vaccine efficacy, lowered dose, and simple and cost-effective process of producing the coated nanoliposomes should be particularly useful in developing potent peptide-based vaccines to prevent infections at the mucosal sites.Export Options
About this article
Cite this article as:
Marasini Nirmal, Ghaffar Abdul Khairunnisa, Giddam Kumar Ashwini, Batzloff R. Michael, Good F. Michael, Skwarczynski Mariusz*, Toth Istvan*, Highly Immunogenic Trimethyl Chitosan-based Delivery System for Intranasal Lipopeptide Vaccines against Group A Streptococcus, Current Drug Delivery 2017; 14 (5) . https://dx.doi.org/10.2174/1567201813666160721141322
DOI https://dx.doi.org/10.2174/1567201813666160721141322 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
Call for Papers in Thematic Issues
Advances of natural products, bio-actives and novel drug delivery system against emerging viral infections
Due to the increasing prevalence of viral infections and the ability of these human pathogens to develop resistance to current treatment strategies, there is a great need to find and develop new compounds to combat them. These molecules must have low toxicity, specific activity and high bioavailability. The most suitable ...read more
Electrospun Fibers as Drug Delivery Systems
In recent years, electrospun fibers have attracted considerable attention as potential platforms for drug delivery due to their distinctive properties and adaptability. These fibers feature a notable surface area-to-volume ratio and can be intentionally designed with high porosity, facilitating an increased capacity for drug loading and rendering them suitable for ...read more
Emerging Nanotherapeutics for Mitigation of Neurodegenerative Disorders
Conditions affecting the central nervous system (CNS) present a significant hurdle due to limited access of both treatments and diagnostic tools for the brain. The blood-brain barrier (BBB) acts as a barrier, restricting the passage of molecules from the bloodstream into the brain. The most formidable challenge facing scientists is ...read more
Nanotechnology Based Chemotherapy for the treatment of Head & Neck Cancer
The escalating recurrence rates observed in Head and Neck cancer, particularly within the chemo-therapeutically treated cohort (50-60%), can be attributed to the non-selective nature of current anticancer drug delivery modalities. In this context, nanotechnology-based drug delivery systems emerge as a promising avenue for achieving precise localization of therapeutic agents to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Progression of Renal Dysfunction in Patients with Cardiovascular Disease
Current Cardiology Reviews The Renin-Angiotensin System: New Insight into Old Therapies
Current Medicinal Chemistry Aging - How Lifestyle Changes Could Prove to be an Effective Medicine for the Aging Cardiovascular System
Current Cardiology Reviews Cardioprotective Effect of Resveratrol and Resveratroloside
Cardiovascular & Hematological Agents in Medicinal Chemistry Posterior Reversible Encephalopathy Syndrome in Leukemic Children: A Sensitive Issue
Current Drug Safety Statins in Aortic Stenosis
Current Pharmaceutical Design Cytomegalovirus Infections in Non-Immunocompromised and Immunocompromised Patients in the Intensive Care Unit
Infectious Disorders - Drug Targets LAT1 Targeted Delivery of Methionine Based Imaging Probe Derived from M(III) Metal Ions for Early Diagnosis of Proliferating Tumours using Molecular Imaging Modalities
Current Cancer Drug Targets Gender Differences in Hemodynamic Regulation and Cardiovascular Adaptations to Dynamic Exercise
Current Cardiology Reviews Biphasic Mechanisms of Neurovascular Unit Injury and Protection in CNS Diseases
CNS & Neurological Disorders - Drug Targets The Wnt Pathway: Emerging Anticancer Strategies
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery A Classical QSAR Study on Some Platelet Aggregation Inhibitors
Mini-Reviews in Medicinal Chemistry Therapy Against Reperfusion-induced Microvascular Injury
Current Pharmaceutical Design Retrospective, Observation Study: Quantitative and Qualitative Effect of Ezetimibe and HMG-CoA Reductase Inhibitors on LDL-Cholesterol: Are There Disappearance Thresholds for Small, Dense LDL and IDL?
Recent Patents on Cardiovascular Drug Discovery The Role of Vascular Aging in Atherosclerotic Plaque Development and Vulnerability
Current Pharmaceutical Design Peroxisome Proliferator-Activated Receptor (PPAR)β /δ: A New Potential Therapeutic Target for the Treatment of Metabolic Syndrome
Current Molecular Pharmacology Platelet Function and Antiplatelet Therapy in Cardiovascular Disease: Implications of Genetic Polymorphisms
Current Vascular Pharmacology Structural and Functional Determinants of γ-Secretase, an Intramembrane Protease Implicated in Alzheimers Disease
Current Genomics Pharmaceuticals and Cosmeceuticals Based on Soft Nanotechnology Techniques with Antioxidative, Immunostimulative and other Therapeutic Activities
Recent Patents on Nanotechnology Oxidative Stress in the ICU
Current Nutrition & Food Science